osi-461
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2001 (NCT00073489)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 6CINHIBITOR
PDE6C inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- (5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(n-benzyl)-indene)-acetamide hydrochloride
- cp 461
- cp-461
- cp-461
- cp-461
- cp461 cpd
- osi461
- osi 461
- osi-461
- osi-461
- osi-461
- osi-461
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00060710 | Phase 2 | Jan 1, 2003 | Astellas, OSI Pharmaceuticals |
| NCT00042055 | Phase 2 | Jul 1, 2002 | Astellas, OSI Pharmaceuticals |
| NCT00036257 | Phase 1 | Mar 1, 2002 | Astellas, OSI Pharmaceuticals |
| NCT00036075 | Phase 2 | Aug 1, 2001 | Astellas, OSI Pharmaceuticals |
| NCT00036036 | Phase 2 | Jul 1, 2001 | Astellas, OSI Pharmaceuticals |
| NCT00073489 | Phase 2 | May 1, 2001 | Astellas, OSI Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 6 | 6 | 2 | 2001 |
| OSI Pharmaceuticals | For profit | 6 | 0 | 2 | 2001 |
2 organizations
Page 1 / 1